BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17203365)

  • 1. 3D-QSAR study of hallucinogenic phenylalkylamines by using CoMFA approach.
    Zhang Z; An L; Hu W; Xiang Y
    J Comput Aided Mol Des; 2007 Apr; 21(4):145-53. PubMed ID: 17203365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of polychlorinated phenols and evaluation of their toxicity, biodegradation and bioconcentration using three-dimensional quantitative structure-activity relationship models.
    Tong L; Guo L; Lv X; Li Y
    J Mol Graph Model; 2017 Jan; 71():1-12. PubMed ID: 27825025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CoMFA and CoMSIA 3D-QSAR analysis of diaryloxy-methano-phenanthrene derivatives as anti-tubercular agents.
    Shagufta ; Kumar A; Panda G; Siddiqi MI
    J Mol Model; 2007 Jan; 13(1):99-109. PubMed ID: 16858589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
    Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
    J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA.
    Doddareddy MR; Jung HK; Cha JH; Cho YS; Koh HY; Chang MH; Pae AN
    Bioorg Med Chem; 2004 Apr; 12(7):1613-21. PubMed ID: 15028254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies.
    Peng Y; Keenan SM; Zhang Q; Kholodovych V; Welsh WJ
    J Med Chem; 2005 Mar; 48(5):1620-9. PubMed ID: 15743203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
    Puntambekar D; Giridhar R; Yadav MR
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of octanol-air partition coefficients for polychlorinated biphenyls (PCBs) using 3D-QSAR models.
    Chen Y; Cai X; Jiang L; Li Y
    Ecotoxicol Environ Saf; 2016 Feb; 124():202-212. PubMed ID: 26524653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CoMFA study of piperidine analogues of cocaine at the dopamine transporter: exploring the binding mode of the 3 alpha-substituent of the piperidine ring using pharmacophore-based flexible alignment.
    Yuan H; Kozikowski AP; Petukhov PA
    J Med Chem; 2004 Dec; 47(25):6137-43. PubMed ID: 15566285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
    da Cunha EF; Sippl W; de Castro Ramalho T; Ceva Antunes OA; de Alencastro RB; Albuquerque MG
    Eur J Med Chem; 2009 Nov; 44(11):4344-52. PubMed ID: 19616874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.
    Opera TI; Waller CL; Marshall GR
    Drug Des Discov; 1994 Jul; 12(1):29-51. PubMed ID: 7578806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CoMFA and CoMSIA 3D-QSAR studies on quionolone caroxylic acid derivatives inhibitors of HIV-1 integrase.
    Lu P; Wei X; Zhang R
    Eur J Med Chem; 2010 Aug; 45(8):3413-9. PubMed ID: 20488589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docking-based CoMFA and CoMSIA studies on naphthyl-substituted diarylpyrimidines as NNRTIs.
    Wu HQ; Yao J; He QQ; Chen FE
    SAR QSAR Environ Res; 2014; 25(10):761-75. PubMed ID: 25242254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CoMFA and CoMSIA studies of angiotensin (AT1) receptor antagonists.
    Datar P; Desai P; Coutinho E; Iyer K
    J Mol Model; 2002 Oct; 8(10):290-301. PubMed ID: 12483229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D-QSAR studies on the inhibitors of AP-1 and NF-kappaB mediated transcriptional activation.
    Qin J; Liu H; Li J; Ren Y; Yao X; Liu M
    Eur J Med Chem; 2009 Jul; 44(7):2888-95. PubMed ID: 19128859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational Analysis of CRTh2 receptor antagonist: A Ligand-based CoMFA and CoMSIA approach.
    Babu S; Sohn H; Madhavan T
    Comput Biol Chem; 2015 Jun; 56():109-21. PubMed ID: 25935115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insight into the structural requirements of proton pump inhibitors based on CoMFA and CoMSIA studies.
    Nayana MR; Sekhar YN; Nandyala H; Muttineni R; Bairy SK; Singh K; Mahmood SK
    J Mol Graph Model; 2008 Oct; 27(3):233-43. PubMed ID: 18676164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists.
    Doddareddy MR; Cho YS; Koh HY; Pae AN
    Bioorg Med Chem; 2004 Aug; 12(15):3977-85. PubMed ID: 15246074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.